雷珠单抗联合光动力疗法治疗湿性年龄相关性黄斑变性的黄斑形态学变化分析被引量：4

Morphological analysis of macula in wet age-related macular degeneration after treatment of Ranibizumab combined with PDT

下载PDF

导出

摘要目的分析雷珠单抗联合光动力疗法(PDT)治疗湿性年龄相关性黄斑变性的黄斑形态学变化。方法收集湿性年龄相关性黄斑变性患者57例(1眼/例)并分为观察组30例(雷珠单抗联合光动力疗法)和对照组27例(雷珠单抗单药治疗)。比较两组治疗后黄斑形态学的变化。结果治疗后黄斑中心凹厚度(CMT)及病变面积均呈下降趋势(P <0.05),观察组下降幅度高于对照组。治疗后1个月下降幅度最大,观察组和对照组CMT下降幅度分别为(87.5±12.8)和(60.1±16.6)μm;观察组和对照组黄斑病变面积减少幅度分别为(2.5±0.6)和(1.8±0.7)mm^2。治疗后12个月观察组和对照组黄斑病变面积减少有效率分别为93.3%和77.8%。结论与单药治疗相比,雷珠单抗联合光动力疗法更能提高黄斑形态学改善的效果。 Objective To retrospectively analyze morphological change of macula in wet age-related macular degeneration(wAMD)after treatment of Ranibizumab combined with photodynamic therapy(PDT).Methods Fifty-seven patients(57 eyes)with wAMD were assigned to observed group(30 eyes)with the regimen of Ranibizumab combined with PDT and control group(27 eyes)with Ranibizumab monotherapy.The change of macular morphology including the central macular thickness(CMT)and area of lesion(AOL)in macular between the two groups werecompared.Results After treatment,both CMT and AOL decreased over time compared with the baseline(P<0.05).The declines of CMT and AOL in the observed group were more marked than control group(P<0.05).The declines of CMT and AOL were maximal at the first month after therapy.The decline of CMT was(87.5±12.8)μm in the observed group and(60.1±16.6)μm in control group.The decline of AOL was(2.5±0.6)mm2 in observation group and(1.8±0.7)mm2 in control group.At the twelfth month of follow-up,the effective rate of the improvement of AOL in the observed group(93.3%)was higher than the control group(77.8%)(P<0.05).Conclusions Compared with the monotherapy,Ranibizumab combined with PDT towards wAMD is more effective in the improvement of macular morphology.

作者王潆秦丹索琰徐转转王旭晁瑞洁王小堂王润生 Ying Wang;Dan Qin;Yan Suo;Zhuan-zhuan Xu;Xu Wang;Rui-jie Chao;Xiao-tang Wang;Run-sheng Wang(Department of Ophthalmology,Xi’an Honghui Hospital affiliated to Xi’an Jiaotong University,Xi'an,Shanxi 710054,China;Department of Ophthalmology,Xi’an No.1 Hospital,Xi'an,Shanxi 710002,China;Department of Ophthalmology,Xi’an No.4 Hospital,Xi'an,Shanxi 710004,China)

机构地区西安交通大学附属红会医院眼科陕西省西安市第一医院眼科陕西省西安市第四医院眼科

出处《中国现代医学杂志》 CAS 2018年第36期105-108,共4页 China Journal of Modern Medicine

关键词湿性黄斑变性雷珠单抗光动力疗法黄斑形态学 wet macular degeneration Ranibizumab photodynamic therapy macular morphology

分类号 R774.5 [医药卫生—眼科]

引文网络
相关文献

参考文献5

1田军.玻璃体腔注射雷珠单抗联合PDT治疗湿性年龄相关性黄斑变性的临床观察[J].医药论坛杂志,2015,36(2):152-154. 被引量：8
2闫磐石,万光明,董一,钱诚,陈悦,李福祯,梁申芝.雷珠单抗联合光动力疗法对年龄相关性黄斑变性CNV的治疗效果[J].国际眼科杂志,2017,17(5):933-936. 被引量：9
3胡军平,杨华,李国栋,陈静,李冬莉,蔡宁,龚翊,庞文毅,袁玲.光动力疗法联合玻璃体内注射雷珠单抗治疗湿性年龄相关性黄斑变性后黄斑区中心视野的改变[J].眼科新进展,2015,35(11):1039-1043. 被引量：15
4李铭,魏伟.湿性年龄相关性黄斑变性的治疗进展[J].国际眼科杂志,2015,15(2):251-254. 被引量：27
5杨雪艳,何锦贤,梁先军,曾胜.PDT联合ranibizumab玻璃体腔注射治疗年龄相关性黄斑变性合并CNV[J].国际眼科杂志,2015,15(4):659-661. 被引量：4

二级参考文献80

1Lim LS, Mitchell P, Seddon JM, et al. Age- related macular degeneration. Lancet 2012 ;379 : 1728-1738.
2Fem6ndez-Robredo P, Sancho A, Johnen S,et al. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering . Ophthalmology 2014;10 (1):1-13.
3Kuo HK, Kao MT, Chen Y J, et al. TranspupiUary thermotherapy inChinese patients with choroidal neovasculafization secondary to age- related macular degeneration: Emphasis on the influence of power setting. Ophthalmologica2008;222(2) :117-122.
4Szentmary N, Goebels S, Bischoff M,et al. Photodynamic therapy for infectious keratitis. Ophthalmologe 2012 ; 109 ( 2 ) : 165-170 .
5Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and hevacizumab for treatment of neovascular age- related macular degeneration: two-year results. Ophtha/mo/ogy 2012;119(7) :1388-1398.
6Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovaseular age- related macular degeneration: a phase Ⅰ/Ⅱ multicenter, controlled, multidose study. Ophthalmology 2006 ; 113 (4) :633-637.
7Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovaseular age-related maeular degeneration. Ophthalmology 2012 ;23 (3) :182-188.
8Rofagha S, Bhisitkul RB, Boyer DS,et al . Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study ( SEVEN - UP). Ophthalmology 2013 ; 120 ( 11 ) :2292-2299.
9Schraermeyer U, Julien S. Ects of bevaeizumab in retina and ehoroid a er intravitreal injection into monkey eyes. Expert Opin Biol TILer 2013 ; 13(2) :157-167.
10Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibereept for the treatment of patients with neovascular age- related macular degeneration. Clin Ophthalmol 2013 ;7:495-501.